His scientific interests lie mostly in Cancer research, Immunology, Melanoma, Dentistry and Cancer. His Cancer research research is multidisciplinary, relying on both Cell, Ovarian cancer, Kinase and Merkel cell carcinoma. His biological study spans a wide range of topics, including Oncology, Pathology, Internal medicine, Matrix metalloproteinase and Metastasis.
Jürgen C. Becker has researched Internal medicine in several fields, including Gastroenterology and Surgery. The Dentistry study combines topics in areas such as Peri-implantitis, Implant and Er:YAG laser. His Antigen study combines topics from a wide range of disciplines, such as Cytotoxic T cell and Survivin.
The scientist’s investigation covers issues in Cancer research, Melanoma, Immunology, Internal medicine and Dentistry. In his work, Skin cancer is strongly intertwined with Merkel cell carcinoma, which is a subfield of Cancer research. His research integrates issues of Metastasis and Pathology in his study of Melanoma.
Many of his studies involve connections with topics such as Cytotoxic T cell and Immunology. The various areas that Jürgen C. Becker examines in his Internal medicine study include Gastroenterology and Oncology. His work deals with themes such as Titanium and Peri-implantitis, Implant, which intersect with Dentistry.
Jürgen C. Becker mainly investigates Cancer research, Merkel cell carcinoma, Melanoma, Internal medicine and Oncology. The concepts of his Cancer research study are interwoven with issues in Cell culture, CD8, Antigen, microRNA and Lymphoma. His research in Antigen intersects with topics in Downregulation and upregulation and T-cell receptor.
His work carried out in the field of Merkel cell carcinoma brings together such families of science as Carcinogenesis, Gene expression and Skin cancer. His Melanoma study also includes
Jürgen C. Becker focuses on Cancer research, Internal medicine, Melanoma, Oncology and Merkel cell carcinoma. His studies in Cancer research integrate themes in fields like Cell culture, T cell, Antigen presentation, Lymphoma and Immunotherapy. His Immunotherapy study incorporates themes from Blockade and CD8.
Jürgen C. Becker studies Melanoma, focusing on Metastatic melanoma in particular. In his research, Survival analysis is intimately related to Immune checkpoint, which falls under the overarching field of Oncology. His work in Merkel cell carcinoma addresses issues such as Antigen, which are connected to fields such as Cell, Gene knockdown, Cell growth and Cancer cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan.
The New England Journal of Medicine (2012)
Antibody targeted drugs as cancer therapeutics
David Schrama;Ralph A. Reisfeld;Jürgen C. Becker.
Nature Reviews Drug Discovery (2006)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker;Marie-France Demierre;Ellen J. Kim;Alain H. Rook.
Journal of Clinical Oncology (2010)
Germline mutations in BAP1 predispose to melanocytic tumors
Thomas Wiesner;Anna C Obenauf;Anna C Obenauf;Rajmohan Murali;Isabella Fried.
Nature Genetics (2011)
Cytotoxic T Cells
Mads Hald Andersen;David Schrama;Per thor Straten;Jürgen C. Becker.
Journal of Investigative Dermatology (2006)
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
D. Schadendorf;S. Ugurel;B. Schuler-Thurner;F.O. Nestle.
Annals of Oncology (2006)
Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution
Line Pedersen;Manja Idorn;Gitte H. Olofsson;Britt Lauenborg.
Cell Metabolism (2016)
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis.
S Strömblad;J C Becker;M Yebra;P C Brooks.
Journal of Clinical Investigation (1996)
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.
Andreas G Niethammer;Rong Xiang;Jürgen C Becker;Harald Wodrich.
Nature Medicine (2002)
Biodegradation of differently cross-linked collagen membranes: an experimental study in the rat.
Daniel Rothamel;Frank Schwarz;Martin Sager;Monika Herten.
Clinical Oral Implants Research (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: